1.

L'Alembic / de la Ligue / Pasquin / et / Marforio Apoticaires / Distribuans les remedes propres / à purger les Maladies / des alliez : [estampe]

2.

L'Alembic / de la Ligue / Pasquin / et / Marforio Apoticaires / Distribuans les remedes propres / à purger les Maladies / des alliez : [estampe]

3.

L'Alembic / de la Ligue / Pasquin / et / Marforio Apoticaires / Distribuans les remedes propres / à purger les Maladies / des alliez : [estampe]

4.

L'Alembic / de la Ligue / Pasquin / et / Marforio Apoticaires / Distribuans les remedes propres / à purger les Maladies / des alliez : [estampe]

1.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium

2.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium

3.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium

4.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium

5.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium

6.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium

7.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium

8.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium

9.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium

1.

Update of the characteristics of Group B Streptococci (GBS) colonizing pregnant women in Belgium: capsular-type distribution, pili characterization, antimicrobial susceptibility pr...

2.

Update of the characteristics of Group B Streptococci (GBS) colonizing pregnant women in Belgium: capsular-type distribution, pili characterization, antimicrobial susceptibility pr...

3.

Update of the characteristics of Group B Streptococci (GBS) colonizing pregnant women in Belgium: capsular-type distribution, pili characterization, antimicrobial susceptibility pr...

4.

Update of the characteristics of Group B Streptococci (GBS) colonizing pregnant women in Belgium: capsular-type distribution, pili characterization, antimicrobial susceptibility pr...

1.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

2.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

3.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

4.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

5.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

6.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

7.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

8.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

9.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

1.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

2.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

3.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

4.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

5.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

6.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

7.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

8.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

9.

Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.

1.

Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium.

1.

Current health issues in beech forests : Beech disease in the Ardennes area ; Les Problèmes sanitaires d'actualité en hêtraie : la maladie du Hêtre dans les Ardennes.

2.

Current health issues in beech forests : Beech disease in the Ardennes area ; Les Problèmes sanitaires d'actualité en hêtraie : la maladie du Hêtre dans les Ardennes.

3.

Current health issues in beech forests : Beech disease in the Ardennes area ; Les Problèmes sanitaires d'actualité en hêtraie : la maladie du Hêtre dans les Ardennes.

4.

Current health issues in beech forests : Beech disease in the Ardennes area ; Les Problèmes sanitaires d'actualité en hêtraie : la maladie du Hêtre dans les Ardennes.

5.

Current health issues in beech forests : Beech disease in the Ardennes area ; Les Problèmes sanitaires d'actualité en hêtraie : la maladie du Hêtre dans les Ardennes.

6.

Current health issues in beech forests : Beech disease in the Ardennes area ; Les Problèmes sanitaires d'actualité en hêtraie : la maladie du Hêtre dans les Ardennes.

7.

Current health issues in beech forests : Beech disease in the Ardennes area ; Les Problèmes sanitaires d'actualité en hêtraie : la maladie du Hêtre dans les Ardennes.

8.

Current health issues in beech forests : Beech disease in the Ardennes area ; Les Problèmes sanitaires d'actualité en hêtraie : la maladie du Hêtre dans les Ardennes.

9.

Current health issues in beech forests : Beech disease in the Ardennes area ; Les Problèmes sanitaires d'actualité en hêtraie : la maladie du Hêtre dans les Ardennes.

1.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

2.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

3.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

4.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

5.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

6.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

7.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

8.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

9.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

1.

Genetic characteristics and antimicrobial resistance of Staphylococcus epidermidis isolates from patients with catheter-related bloodstream infections and from colonized healthcare...

2.

Genetic characteristics and antimicrobial resistance of Staphylococcus epidermidis isolates from patients with catheter-related bloodstream infections and from colonized healthcare...

3.

Genetic characteristics and antimicrobial resistance of Staphylococcus epidermidis isolates from patients with catheter-related bloodstream infections and from colonized healthcare...

4.

Genetic characteristics and antimicrobial resistance of Staphylococcus epidermidis isolates from patients with catheter-related bloodstream infections and from colonized healthcare...

5.

Genetic characteristics and antimicrobial resistance of Staphylococcus epidermidis isolates from patients with catheter-related bloodstream infections and from colonized healthcare...

6.

Genetic characteristics and antimicrobial resistance of Staphylococcus epidermidis isolates from patients with catheter-related bloodstream infections and from colonized healthcare...

7.

Genetic characteristics and antimicrobial resistance of Staphylococcus epidermidis isolates from patients with catheter-related bloodstream infections and from colonized healthcare...

8.

Genetic characteristics and antimicrobial resistance of Staphylococcus epidermidis isolates from patients with catheter-related bloodstream infections and from colonized healthcare...

9.

Genetic characteristics and antimicrobial resistance of Staphylococcus epidermidis isolates from patients with catheter-related bloodstream infections and from colonized healthcare...

1.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

2.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

3.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

4.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...